Mar 18, 2021
Dr. Mark Allen, Co-Founder and CEO, Elevian is looking to disrupt the longevity business by developing a recombinant GDF11 to treat and prevent multiple age-related diseases. The first application being investigated is for stroke recovery drawing on the discovery that GDF11 decreases with age and when replenished, returns the brain to a healthier pattern of vascularization. Not looking to extend just the life span, the goal is to target the aging process and extend the healthy lifespan.
@ElevianInc #aging #StrokeRecovery #AgeRelatedDisease #GDF11